Gufic Biosciences Ltd - Stock Valuation and Financial Performance

BSE: 509079 | NSE: GUFICBIO | Pharmaceuticals & Drugs | Small Cap

Gufic Biosciences Share Price

312.95 2.70 0.87%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Gufic Biosciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Gufic Biosciences stock performance -

mw4me loader
P/E Ratio (SA):
37.27
Market Cap:
3,138.2 Cr.
52-wk low:
192
52-wk high:
364

Is Gufic Biosciences Ltd an attractive stock to invest in?

1. Is Gufic Biosciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gufic Biosciences Ltd is a average quality company.

2. Is Gufic Biosciences Ltd undervalued or overvalued?

The key valuation ratios of Gufic Biosciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Gufic Biosciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Gufic Biosciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Gufic Biosciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gufic Biosciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 11.8%12.5%17.5%15.3%18.7%18.8%15.6%22.2%35.4%17.7%-
Value Creation
Index
-0.2-0.10.30.10.30.30.10.61.50.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 123152202246306351379488779691785
Sales YoY Gr.-23.2%33.4%21.4%24.5%14.8%8%28.7%59.8%-11.4%-
Adj EPS 0.50.611.11.92.82.44.59.88.48.4
YoY Gr.-3.7%76.8%12.1%74.8%43.3%-15.1%89%120.4%-14.2%-
BVPS (₹) 3.43.54.44.879.713.317.927.835.951.2
Adj Net
Profit
4.14.37.68.615.121.722.943.295.381.884
Cash Flow from Ops. 10.911.2-4.3-4.1-4.85.247.187.3106-26.6-
Debt/CF from Ops. 3.12.9-9.9-13.7-16.518.82.50.60.6-11.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 21.1%17.7%22.2%-11.4%
Adj EPS 35.7%34.2%52.9%-14.2%
BVPS30%38.8%39.1%29.3%
Share Price 47.8% 30.7% 39.9% 55.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
1716.22524.23333.522.328.543.126.519.3
Op. Profit
Mgn %
9.89.6109.412.713.113.817.21919.918.3
Net Profit
Mgn %
3.42.93.83.54.96.268.912.211.810.7
Debt to
Equity
1.31.21.31.51.51.30.90.30.20.9-
Working Cap
Days
192199187190201239295221130187114
Cash Conv.
Cycle
3723406786738447315537

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 22.16%

Net Profit is growing at healthy rate in last 3 years 52.86%

Sales growth is good in last 4 quarters at 15.32%

Return on Equity has declined versus last 3 years average to 19.30%

Latest Financials - Gufic Biosciences Ltd.

Standalone Consolidated
TTM EPS (₹) 8.4 -
TTM Sales (₹ Cr.) 785 -
BVPS (₹.) 51.2 -
Reserves (₹ Cr.) 503 -
P/BV 6.12 -
PE 37.27 -
From the Market
52 Week Low / High (₹) 192.00 / 364.00
All Time Low / High (₹) 0.17 / 364.00
Market Cap (₹ Cr.) 3,138
Equity (₹ Cr.) 10
Face Value (₹) 1
Industry PE 48

Management X-Ray of Gufic Biosciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Gufic Biosciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales123152202246306351379488779691
Operating Expenses 111137183223267305327404631556
Manufacturing Costs20192732414751579387
Material Costs567391107129161156226368295
Employee Cost 12193241454759668687
Other Costs 23263342525060558486
Operating Profit 1214202339465284148135
Operating Profit Margin (%) 9.8%9.4%9.7%9.3%12.7%13.1%13.8%17.2%19.0%19.5%
Other Income 1111346433
Interest 4466910141458
Depreciation 24444514161922
Exceptional Items 0000200000
Profit Before Tax 67101430353058127107
Tax 223513137133127
Profit After Tax 4479162223449680
PAT Margin (%) 3.5%2.7%3.6%3.7%5.4%6.3%6.0%9.1%12.3%11.5%
Adjusted EPS (₹)0.60.51.01.22.12.82.34.69.98.2
Dividend Payout Ratio (%)9%9%5%4%2%2%2%2%1%1%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 262734375475129173269348
Share Capital 88888810101010
Reserves 181926304668120164259338
Minority Interest0000000000
Debt3029405477961135255302
Long Term Debt151287811203548191
Short Term Debt15183247698593167112
Trade Payables325053447678117111141130
Others Liabilities 232126402861134565780
Total Liabilities 111127152175235310493392521860

Fixed Assets

Gross Block485151263137115149180246
Accumulated Depreciation182629481332496487
Net Fixed Assets30252222232483100115160
CWIP 0000210311341170
Investments 0000000001
Inventories26375063949412294116183
Trade Receivables2833565281103107125152205
Cash Equivalents 36667816132747
Others Assets242617322871134477295
Total Assets 111127152175235310493392521860

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 1111-4-4-554787106-27
PBT 67111430353058127107
Adjustment 68910121325312330
Changes in Working Capital -0-2-21-24-30-3428-11-135
Tax Paid -1-2-3-5-16-10-10-9-33-28
Cash Flow From Investing Activity -3-2-1-5-9-13-43-7-95-191
Capex -3-3-1-4-8-13-40-12-87-188
Net Investments 000000000-1
Others 000-1-10-36-7-2
Cash Flow From Financing Activity -7-557148-4-79-6234
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -4-3-400371212107
Interest Paid -4-4-5-6-8-10-13-12-5-8
Dividend Paid 00000000-1-1
Others 13141423151-78-12136
Net Cash Flow 140-11002517
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)17.5515.623.9925.3136.0333.8922.1729.2243.3125.84
ROCE (%)17.4518.3824.2424.2634.129.6521.0130.0547.2923.23
Asset Turnover Ratio1.31.341.531.591.551.320.981.171.861.16
PAT to CFO Conversion(x)2.752.75-0.57-0.44-0.310.232.041.981.1-0.34
Working Capital Days
Receivable Days68707676769398815981
Inventory Days657274799095101764568
Payable Days170202205164170174227184125168

Gufic Biosciences Ltd Stock News

Gufic Biosciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Gufic Biosciences on 12-Apr-2024 16:59 is ₹312.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Gufic Biosciences stood at ₹3,138.2.
The latest P/E ratio of Gufic Biosciences as of 12-Apr-2024 16:59 is 37.27.
The latest P/B ratio of Gufic Biosciences as of 12-Apr-2024 16:59 is 6.12.
The 52-week high of Gufic Biosciences is ₹364.0 and the 52-week low is ₹192.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gufic Biosciences is ₹784.7 ( Cr.) .

About Gufic Biosciences Ltd

The company been in the Pharmaceutical industry since 1970 and is known and respected for Innovative and high Quality pharmaceutical and Herbal Products along with a wide range of APIs.

The company is one of the largest manufacturers of Lyophilized injections in India and has a fully automated lyophilization plant. Its lyophillized product portfolio includes Antibiotic, Antifungal, Cardiac, Infertility, Antiviral and proton-pump inhibitor segments.

The company’s products are supplied to most major hospital chains and leading medical facilities and it has an extensive network of representatives promoting these products all across India.

The company combines its high end Lyophilisation technology with R&D expertise to create differentiated products targeted at domestic and international markets. It has set up one of the largest and state of the art lyophilisation facility with major accreditations like EU-GMP, WHO-GMP, Ukraine-GMP.

Business area of the company

The company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

Products of the company

  • Pharmaceutical
  • Herbal
  • API / Bulk Drugs
  • Personal care
  • International

History and milestone

Past Initiatives

  • First Indian to produce Doxycycline Inj.
  • First Indian company to make Liquid Oxytetracycline Inj.
  • Mox (Amoxicillin) and Zole ointment featured among the top 100 pharma brands
  • First Company to launch Boswellia Serrata tablets
  • Pioneer in developing Kid tablet in India
  • Hived off Mox and Zole to Ranbaxy

2007-2009

  • Initiated contract manufacturing
  • Commenced international exports

2010-2015

  • Received patents for Anidulafungin and Tigecycline lyophilized inj.
  • Launched Criticare division

2016

  • Set up a full automatic state of the art facility at Navsari, India under the name Gufic Lifesciences Pvt ltd and received EU GMP approval
  • Launched Ferticare and Criticare Life divisions

2017-2019

  • Received patents for Rifabutin and Micafunginlyophilized inj.
  • Exported Vancomycin lyophilized Inj. to Germany
  • Manufacturing capacity ramped up to 31 million vials per annum
  • Launched Ferticare Life division

2020

  • Manufacturing Remdesivir for Hetero
  • Increased capacity to 48 million vials per annum

2022

  • Incorporated wholly owned subsidiary company namely ‘Gufic UK’
  • Received DCGI approval for Thymosin Alpha-1 (Immunocin - A Brand of Gufic for the said drug)
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.